All In Biotech

Drug Trial Radar · NCT00426660

Expanded Access Program for Maraviroc At Multiple Centers

A Multicenter, Open Label, Expanded Access Trial Of Maraviroc

Last checked: Nov 20, 2026Latest source record: Jun 29, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,047

Actual

Start

Feb 2007

Primary completion

Jun 2010

Study completion Jun 2010

Sponsor

Lead sponsor
ViiV HealthcareGSK (GSK)
Sponsor type
Industry
First posted
Jan 25, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Primary purpose
Treatment
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To provide access to maraviroc to patients who have limited or no therapeutic treatment options and to collect more safety data in a broader patient population.

Conditions

  • HIV Infections

Interventions

  • maravirocDrug

    The nominal dose for maraviroc is 300 mg twice a day (BID). However, the dosage of maraviroc should be adjusted based on optimal background therapy (OBT) patient is taking. If OBT includes CYP3A4 inhibitor (with or without inducers) maraviroc dose should be 150 mg BID and if OBT includes CYP3A4 inducer (without inhibitors) maraviroc dose should be 600mg BID. If OBT does not include any CYP3A4 inducers or inhibitors maraviroc dose should be 300 mg BID.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Grade 3 and Grade 4 Adverse Events (AE)Time frame: Baseline up to Week 144
  2. Percentage of Participants With Grade 3 Laboratory Abnormalities Without Regards to Baseline AbnormalitiesTime frame: Baseline up to Week 144
  3. Percentage of Participants With Grade 4 Laboratory Abnormalities Without Regards to Baseline AbnormalitiesTime frame: Baseline up to Week 144
  4. Percentage of Participants With Acquired Immunodeficiency Syndrome (AIDS)-Defining IllnessesTime frame: Baseline up to Week 144
  5. Percentage of Participants With Possible Acquired Immunodeficiency Syndrome (AIDS) Related Infections and Malignancies by Baseline Viral LoadTime frame: Baseline up to Week 144
  6. Percentage of Participants With Possible Acquired Immunodeficiency Syndrome (AIDS) Related Infections and Malignancies by Baseline/Nadir CD4 Cell CountsTime frame: Baseline up to Week 144
  7. Percentage of Participants With Possible Acquired Immunodeficiency Syndrome (AIDS) Related Infections and Malignancies by Time on TherapyTime frame: Baseline up to Week 144
  8. Percentage of Participants With All Causality Treatment-emergent Adverse (AEs) Events by GenderTime frame: Baseline up to Week 144
  9. Percentage of Participants With Treatment-emergent Adverse Events (AEs) by RaceTime frame: Baseline up to Week 144
  10. Percentage of Participants With Treatment-emergent Adverse Events (AEs) by AgeTime frame: Baseline up to Week 144
  11. Percentage of Participants With Treatment-emergent Averse Events (AEs) by Baseline Hepatitis B and Hepatitis C Virus Serology StatusTime frame: Baseline up to Week 144

Locations

361 sites in 26 countries. Site status is shown where the registry gives one.

  • The University of Alabama

    Birmingham, Alabama

  • Health Services Center

    Hobson City, Alabama

  • El Rio, Special Immunology Associates

    Tucson, Arizona

  • Health for Life Clinic PLLC

    Little Rock, Arkansas

  • Thomas T Jefferson, MD

    Little Rock, Arkansas

  • Vista Medical

    Beverly Hills, California

  • AHF Research Center

    Beverly Hills, California

  • Orange County Center for Special Immunology

    Fountain Valley, California

  • Kaiser Permanente

    Hayward, California

  • Living Hope Clinical Trials

    Long Beach, California

  • AltaMed Health Services Corporation

    Los Angeles, California

  • Kaiser Permanente Medical Center

    Los Angeles, California

  • Robert Bolan, MD

    Los Angeles, California

  • Maternal-Child and Adolescent Clinic of Infectious Diseases and Virology

    Los Angeles, California

  • Peter J. Ruane, M.D. Inc.

    Los Angeles, California

  • Synergy Hematology-Oncology Associates

    Los Angeles, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • Erlmed Corp ABA Lim-Keith Muiltispecialty Clinic Inc.

    Los Angeles, California

  • Office of Anthony Mills, MD

    Los Angeles, California

  • Office of Dr. Salah Bibi, MD

    Modesto, California

  • Bonnie V Bock MD

    Newport Beach, California

  • Alta Bates Summit Medical Center

    Oakland, California

  • Desert Medical Group, Clinical Research Center

    Palm Springs, California

  • Riverside Medical Clinic

    Riverside, California

  • Fort Sutter Medical Complex

    Sacramento, California

  • Sutter Institute for Medical Research

    Sacramento, California

  • Sutter Medical Group

    Sacramento, California

  • Quest Clinical Research

    San Francisco, California

  • Kaiser Permanente Medical Center

    San Francisco, California

  • Kaiser Permanente Santa Clara

    Santa Clara, California

  • Shared Medical Research Foundation

    Tarzana, California

  • Tarzana Treatment Center

    Tarzana, California

  • Bipin Bhagat MD Inc.

    Victorville, California

  • Kaiser Permanente Colorado

    Denver, Colorado

  • Kaiser Permanente of Colorado

    Denver, Colorado

  • Denver Infectious Disease Consultants, PLLC

    Denver, Colorado

  • Kaiser Permanente of Colorado

    Lafayette, Colorado

  • Connecticut Health Care Group

    Glastonbury, Connecticut

  • Infectious Disease Clinic

    Norwich, Connecticut

  • Dupont Circle Physicians Group

    Washington D.C., District of Columbia

Showing 40 of 361 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.